12:00 AM
 | 
Jul 01, 2002
 |  BioCentury  |  Finance

Selected second quarter approvals and setbacks

Selected second quarter approvals and setbacks

Company Approval
Actelion Europe approves Tracleer bosentan to treat pulmonary arterial hypertension
Alliance FDA approves Imagent ultrasound contrast agent for cardiac imaging
Andrx FDA approves Altocor extended release lovastatin for cholesterol disorders
Biogen FDA issues complete response letter for Amevive alefacept to treat psoriasis
Biovail FDA approves once-daily Cardizem XL to treat hypertension
Cerus/Baxter Europe approves Intercept Blood System to inactivate pathogens in platelets; awaiting approval of illumination device
Gilead Europe approves Tamiflu oseltamivir to treat and prevent influenza
Eden...

Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >